Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety

Figure 1

Intravenous injection of rh-HGF reduced blood pressure through capacitance vessels in miniature swine. Effect of intravenously administered rh-HGF on BP, HR, and cardiac function was examined in miniature swine under general anesthesia. (A) Intravenous injection of rh-HGF (1.0 mg/kg) rapidly reduced systolic and diastolic BP. Reduced BP was persistent during rh-HGF administration (for 20 min), and was immediately recovered after the rh-HGF injection. Echocardiography showed that ejection fraction (EF) and left ventricular end-diastolic volume (LVEDV) were reduced during rh-HGF administration. (B) rh-HGF (0.4 mg/kg) administered for three hours with a stepwise increase (0.01 mg/kg for first 60 min, 0.03 mg/kg for the next 60 min, and 0.36 mg/kg for the last 60 min) gradually decreased BP and HR. (C) Infusion of 100 mL of saline prior to rh-HGF administration prevented a decrease in BP during exposure to rh-HGF.

Back to article page